Literature DB >> 25228009

Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells.

Qing Wu1, Yong-Feng Chen, Jie Fu, Qi-Han You, Shou-Mei Wang, Xue Huang, Xiao-Jun Feng, Shu-Hui Zhang.   

Abstract

BACKGROUND: Deregulation of centromere protein (CENP)-A, a centromere-specific histone variant, has in the past been linked to cancer initiation and progression. Additionally, our previous work has shown that CENP-A upregulation predicts a poor overall survival in patients with lung adenocarcinoma. The aim of this study was to uncover the biological role of CENP-A in lung adenocarcinoma growth and invasion, including its underlying molecular mechanisms.
METHODS: CENP-A expression was knocked down in human lung adenocarcinoma A549 and PC-9 cells using a short hairpin RNA (shRNA) technology. Subsequently, the effects of this knock down on the proliferation, apoptosis, cell cycle progression, colony formation, migration, invasion and tumorigenicity were assessed. Additionally, Western blot analyses were performed to examine concomitant expression changes in key proteins involved in cell cycle regulation and apoptosis.
RESULTS: We found that shRNA-mediated knock down of CENP-A significantly inhibited the in vitro proliferation and colony formation of A549 and PC-9 cells as compared to control shRNA-transfected cells. In addition, CENP-A down-regulation was found to induce G0/G1 cell cycle arrest and apoptosis, and to inhibit the in vitro migration and invasion of A549 and PC-9 cells. Down-regulation of CENP-A was also found to significantly suppress the in vivo growth of xenografted A549 cells. At the protein level, we found that the expression of p21, p27, CHK2 and Bax was markedly increased and that the expression of CCNG1, Skp2, Cks1 and Bcl-2 was markedly decreased in CENP-A down-regulated cells.
CONCLUSION: Based on our results we conclude that down-regulation of CENP-A may attenuate the aggressive phenotype of lung adenocarcinoma cells. As such, CENP-A may serve as a promising therapeutic target for lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25228009     DOI: 10.1007/s13402-014-0199-z

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  30 in total

1.  Early disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice.

Authors:  E V Howman; K J Fowler; A J Newson; S Redward; A C MacDonald; P Kalitsis; K H Choo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 2.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

Authors:  Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Jerry M Adams
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01       Impact factor: 94.444

Review 3.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

Review 4.  Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.

Authors:  Paola Ulivi; Rosella Silvestrini
Journal:  Cell Oncol (Dordr)       Date:  2013-11-01       Impact factor: 6.730

5.  The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27.

Authors:  D Ganoth; G Bornstein; T K Ko; B Larsen; M Tyers; M Pagano; A Hershko
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

6.  COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins.

Authors:  Jared Bieniek; Chandra Childress; Matthew D Swatski; Wannian Yang
Journal:  Prostate       Date:  2014-05-07       Impact factor: 4.104

7.  Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma.

Authors:  Shu-Hui Zhang; Ai-Min Xu; Xin-Fang Chen; Di-Hua Li; Man-Ping Sun; Yu-Jia Wang
Journal:  Hum Pathol       Date:  2008-08-20       Impact factor: 3.466

8.  ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth.

Authors:  Yongmei Li; Zhi Zhu; Shuhui Zhang; Danghui Yu; Hongyu Yu; Lina Liu; Xiaozhe Cao; Li Wang; Hengjun Gao; Minghua Zhu
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

9.  Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses.

Authors:  Xiaohong Liu; Li Wang; Shuhui Zhang; Jing Lin; Shunmin Zhang; Mark A Feitelson; Hengjun Gao; Minghua Zhu
Journal:  Carcinogenesis       Date:  2008-05-13       Impact factor: 4.944

10.  Assembly in G1 phase and long-term stability are unique intrinsic features of CENP-A nucleosomes.

Authors:  Dani L Bodor; Luis P Valente; João F Mata; Ben E Black; Lars E T Jansen
Journal:  Mol Biol Cell       Date:  2013-01-30       Impact factor: 4.138

View more
  15 in total

1.  Mitochondrial induction as a potential radio-sensitizer in lung cancer cells - a short report.

Authors:  Ronen Shavit; Maya Ilouze; Tali Feinberg; Yaacov Richard Lawrence; Yossi Tzur; Nir Peled
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

2.  MicroRNA-216b regulated proliferation and invasion of non-small cell lung cancer by targeting SOX9.

Authors:  Sida Liu; Han Dong; Hui Dai; Danwei Liu; Zhihao Wang
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

3.  Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.

Authors:  Yu-Lun Chen; Tsung-Ying Yang; Kun-Chieh Chen; Chieh-Liang Wu; Shih-Lan Hsu; Chi-Mei Hsueh
Journal:  Cell Oncol (Dordr)       Date:  2016-06-15       Impact factor: 6.730

4.  Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells.

Authors:  Zeynep Birsu Cincin; Miray Unlu; Bayram Kiran; Elif Sinem Bireller; Yusuf Baran; Bedia Cakmakoglu
Journal:  Cell Oncol (Dordr)       Date:  2015-04-10       Impact factor: 6.730

5.  RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.

Authors:  Chuan Zeng; Weidong Fan; Xianquan Zhang
Journal:  Cell Oncol (Dordr)       Date:  2015-06-20       Impact factor: 6.730

6.  A positive feedback loop of CENPU/E2F6/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma.

Authors:  Yingyi Liu; Ye Yao; Bo Liao; Hao Zhang; Zhangshuo Yang; Peng Xia; Xiang Jiang; Weijie Ma; Xiaoling Wu; Chengjie Mei; Ganggang Wang; Meng Gao; Kequan Xu; Xiangdong GongYe; Zhixiang Cheng; Ping Jiang; Xi Chen; Yufeng Yuan
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

Review 7.  Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible?

Authors:  R N Sharan; S Thangminlal Vaiphei; Saibadaiahun Nongrum; Joshua Keppen; Mandahakani Ksoo
Journal:  Cell Oncol (Dordr)       Date:  2015-09-18       Impact factor: 6.730

8.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

Review 9.  Altered primary chromatin structures and their implications in cancer development.

Authors:  Angelo Ferraro
Journal:  Cell Oncol (Dordr)       Date:  2016-03-23       Impact factor: 6.730

Review 10.  Guarding the Genome: CENP-A-Chromatin in Health and Cancer.

Authors:  Megan A Mahlke; Yael Nechemia-Arbely
Journal:  Genes (Basel)       Date:  2020-07-16       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.